Table 1.
Notation used in expressing weighted-average per-infection estimates under tetravalent vaccination.
Table 2.
Transmission-related parameters for dengue and Zika, and their estimated values.
All values not identified by source were estimated in this paper; see the first part of the results section for details. * first 25 months, ages 9–16.
Table 3.
Parameters representing proportions of each case type (d1, d2, z2) with various characteristics or outcomes.
Self-managed cases include asymptomatic; ambulatory cases seek treatment; severe nonfatal involve DHF/DSS. See the corresponding results subsection for further detail.
Table 4.
Parameters representing subtype-level average costs (in 2024 USD) for each case type (d1, d2, z2) with various characteristics or outcomes. Self-managed cases include asymptomatic; ambulatory cases seek treatment; severe nonfatal involve DHF/DSS. See Results section for further detail.
Table 5.
Parameters representing top-level average burdens (in DALYs) for each case type (d1, d2, z2) with various characteristics or outcomes; also, average age (in years) at death due to dengue.
Self-managed cases include asymptomatic; ambulatory cases seek treatment; severe nonfatal involve DHF/DSS. See Results section for further detail.
Table 6.
Estimated average costs (in 2024 USD) and burdens (in DALYs) per dengue (D) or Zika (Z) case, or per dengue screening or vaccination series. For each virus, 1 signifies without ADE and 2 with ADE.
Table 7.
Estimated weighted-average per-exposure economic costs (in 2024 USD) and disease burdens (in DALYs) for dengue (where the circulating serotype is either the same as (DS) or different than (DD) that of any prior exposure) and Zika, based on regional prior exposure levels from [21,22], in the absence of dengue vaccination.